Vytorin Bolsters LDL-Lowering Claim Over Lipitor With New Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Ezetimibe/simvastatin advantage over atorvastain is found to be not as great with higher starting doses.
You may also be interested in...
Vytorin Outpaces Crestor In Comparison Study
Schering-Plough/Merck’s ezetimibe/simvastatin combination shows better LDL cholesterol reduction than Crestor.
Vytorin Outpaces Crestor In Comparison Study
Schering-Plough/Merck’s ezetimibe/simvastatin combination shows better LDL cholesterol reduction than Crestor.
Vytorin Data Showing Superiority Over Lipitor Added To Labeling
Merck/Schering-Plough’s labeling update for Vytorin includes results of the VYVA study.